- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement
Nuvo Research Inc. (TSX:NRI) has agreed with Horizon Pharma plc (NASDAQ: HZNP) to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the US market to December 31, 2029, which extends the agreement by an additional seven years. The amended agreement also provides for tiered pricing based on volumes of product supplied.
Nuvo Research Inc. (TSX:NRI) has agreed with Horizon Pharma plc (NASDAQ: HZNP) to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the US market to December 31, 2029, which extends the agreement by an additional seven years. The amended agreement also provides for tiered pricing based on volumes of product supplied.
According to John London, Nuvo’s President and Co-CEO:
This amendment secures the long-term future of the core business of Nuvo Pharmaceuticals, the commercial healthcare company to be 100% owned by Nuvo shareholders upon completion of our previously announced reorganization of Nuvo into two separate, publicly traded companies. We intend to build upon that core business by out-licensing PENNSAID 2% internationally and by seeking to acquire complementary, accretive businesses or products.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.